Doo Yeon Kim, Ph.D.

Assistant Professor of Neurology, Harvard Medical School

Assistant in Neurology, Genetics and Aging Research Unit, Massachusetts General Institute for Neurodegenerative Diseases, Department of Neurology, Massachusetts General Hospital

Dr. Kim received his Ph.D. at Korea Advanced Institute of Science and Technology (KAIST), South Korea. He started his postgraduate work at the Brain Disease Research Center, Ajou University Medical School, South Korea, and completed his post doctorate at Dr. Dora M. Kovacs’ laboratory at Massachusetts General Hospital, where he was appointed assistant professor in 2009. He was awarded a fellowship from the John Douglas French Alzheimer's Foundation in 2004.

Dr. Kim has been investigating physiological and pathological functions of Alzheimer’s disease-related secretases, BACE1 and presenilin/g-secretase, since 2001. BACE1 and g-secretase play a major role in Alzheimer’s disease pathogenesis by regulating Ab-peptide generation.

Funded Research

Project Description Researchers Funding
Stem Cell Consortium Year 2

Stem cells are the least mature cells in the body. Because these cells are so immature, they can be treated with a defined cocktail of factors and, depending on which factors are used and in what sequence, those factors can cause maturation of cells along discrete cell types. With a new tool called induced pluripotent stem cells, it now is possible to take skin cells from adults and return them to this immature state. By redirecting skin cells from Alzheimer’s patients and turning them into nerve cells, we are able to study adult Alzheimer’s neurons (nerve cells) in the lab.

2014
$400,000
Stem Cell Consortium

Stem cells are the least mature cells in the body. Because these cells are so immature, they can be treated with a defined cocktail of factors and, depending on which factors are used and in what sequence, those factors can cause maturation of cells along discrete cell types. With a new tool called induced pluripotent stem cells, it now is possible to take skin cells from adults and return them to this immature state. By redirecting skin cells from Alzheimer’s patients and turning them into nerve cells, we are able to study adult Alzheimer’s neurons (nerve cells) in the lab.

2013
$600,000
Alzheimer Disease Models Based on Human Neural Progenitor Cells

The goal of this project is to develop genetically modified human neural progenitor cells that can replicate Alzheimer’s disease pathology in in vitro and in vivo conditions in order to develop and test Alzheimer disease drugs in human brain cells.

2011
$100,000

Selected Publications

These published papers resulted from Cure Alzheimer’s Fund support.

Jaehong Suh, Se Hoon Choi, Donna M. Romano, Moira A. Gannon, Andrea N. Lesinski, Doo Yeon Kim, Rudolph E. Tanzi, ADAM10 Missense Mutations Potentiate β-Amyloid Accumulation by Impairing Prodomain Chaperone Function, Neuron, 80(2), Oct 16, 2013, 385–401